2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.
In the germline BRCA-mutated group, there was a statistically significant positive hazard ratio in favor of niraparib (Zejula), says Moore.
The exploratory endpoints of this trial were to further characterize the germline BRCA-mutated group. A small group of patients with somatic BRCA mutations was identified and they seemed to get the same benefit from niraparib as the BRCA-mutated patients, Moore adds.